Steven Patierno

Overview:

Patierno's current translational research interests are focused on the genomics molecular biology of cancer disparities, cancer biology, molecular pharmacology and targeted experimental therapeutics to control prostate, breast and lung tumor aggressiveness. He is an internationally recognized expert in cancer control, cancer causation and molecular carcinogenesis, which includes a broad spectrum of laboratory and population level research.   Patierno is also actively engaged in cancer health disparities and healthcare delivery research focused on patient navigation, survivorship, community-based interventions, mHealth, implementation sciences, cancer care economics, and policy.

Positions:

Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Professor of Pharmacology and Cancer Biology

Pharmacology & Cancer Biology
School of Medicine

Professor in Family Medicine and Community Health

Family Medicine and Community Health
School of Medicine

Core Faculty Member, Duke-Margolis Center for Health Policy

Duke - Margolis Center For Health Policy
Institutes and Provost's Academic Units

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.S. 1981

University of Connecticut

Ph.D. 1985

University of Texas Medical School, Houston

Postdoctoral Training, Norris Comprehensive Cancer

University of Southern California

Grants:

3D Biology Signatures defined by Nanostring Max System

Administered By
Medicine, Medical Oncology
Awarded By
North Carolina Biotechnology Center
Role
Major User
Start Date
End Date

Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer

Administered By
Medicine, Medical Oncology
Awarded By
V Foundation for Cancer Research
Role
Significant Contributor
Start Date
End Date

PC150506: Small molecule targeting of RNA splice variants driving tumor aggressiveness

Administered By
Chemistry
Awarded By
United States Army Medical Research Acquisition Activity
Role
Collaborator
Start Date
End Date

2/2 NCCU-DUKE Cancer Disparities Translational Research Partnership

Administered By
Duke Cancer Institute
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Detection of Novel Alternative Splicing Biomarkers of Hypoxia in Breast and Lung Tumors

Administered By
Radiation Oncology
Awarded By
Rsna Research & Education Fund
Role
Mentor
Start Date
End Date

Publications:

Abstract IA18: North Carolina Central University and Duke Cancer Institute's collaborative cancer research and education program: Connecting cancer disparities translational research, clinical trials operations, and community engagement

Authors
Williams, KP; Barrett, NJ; Oldham, CE; Hough, H; Woodard, A; Freedman, J; Devi, GR; Patierno, SR
MLA Citation
Williams, Kevin P., et al. “Abstract IA18: North Carolina Central University and Duke Cancer Institute's collaborative cancer research and education program: Connecting cancer disparities translational research, clinical trials operations, and community engagement.” Oral Presentations  Invited Abstracts, American Association for Cancer Research, 2020. Crossref, doi:10.1158/1538-7755.disp18-ia18.
URI
https://scholars.duke.edu/individual/pub1467305
Source
crossref
Published In
Oral Presentations Invited Abstracts
Published Date
DOI
10.1158/1538-7755.disp18-ia18

A Zebrafish Model of Metastatic Colonization Pinpoints Cellular Mechanisms of Circulating Tumor Cell Extravasation.

Metastasis is a multistep process in which cells must detach, migrate/invade local structures, intravasate, circulate, extravasate, and colonize. A full understanding of the complexity of this process has been limited by the lack of ability to study these steps in isolation with detailed molecular analyses. Leveraging a comparative oncology approach, we injected canine osteosarcoma cells into the circulation of transgenic zebrafish with fluorescent blood vessels in a biologically dynamic metastasis extravasation model. Circulating tumor cell clusters that successfully extravasated the vasculature as multicellular units were isolated under <i>intravital</i> imaging (n = 6). These extravasation-positive tumor cell clusters sublines were then molecularly profiled by RNA-Seq. Using a systems-level analysis, we pinpointed the downregulation of KRAS signaling, immune pathways, and extracellular matrix (ECM) organization as enriched in extravasated cells (p < 0.05). Within the extracellular matrix remodeling pathway, we identified versican (<i>VCAN</i>) as consistently upregulated and central to the ECM gene regulatory network (p < 0.05). Versican expression is prognostic for a poorer metastasis-free and overall survival in patients with osteosarcoma. Together, our results provide a novel experimental framework to study discrete steps in the metastatic process. Using this system, we identify the versican/ECM network dysregulation as a potential contributor to osteosarcoma circulating tumor cell metastasis.
Authors
Allen, TA; Cullen, MM; Hawkey, N; Mochizuki, H; Nguyen, L; Schechter, E; Borst, L; Yoder, JA; Freedman, JA; Patierno, SR; Cheng, K; Eward, WC; Somarelli, JA
MLA Citation
Allen, Tyler A., et al. “A Zebrafish Model of Metastatic Colonization Pinpoints Cellular Mechanisms of Circulating Tumor Cell Extravasation.Frontiers in Oncology, vol. 11, Jan. 2021, p. 641187. Epmc, doi:10.3389/fonc.2021.641187.
URI
https://scholars.duke.edu/individual/pub1498525
PMID
34631514
Source
epmc
Published In
Frontiers in Oncology
Volume
11
Published Date
Start Page
641187
DOI
10.3389/fonc.2021.641187

Mechanistic and functional interrogation of novel ancestry-related alternatively spliced androgen receptor signal genes in prostate cancer

Authors
Onyenwoke, RU; Freedman, JA; Patierno, BM; Eze, C; Dayo, A; George, DJ; Patierno, SR
MLA Citation
Onyenwoke, Rob U., et al. “Mechanistic and functional interrogation of novel ancestry-related alternatively spliced androgen receptor signal genes in prostate cancer.” Cancer Epidemiology Biomarkers & Prevention, vol. 29, no. 6, 2020.
URI
https://scholars.duke.edu/individual/pub1467306
Source
wos-lite
Published In
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Volume
29
Published Date

Abstract 3507: Race-related genetic variation and response to secondary hormonal therapy in metastatic castration-resistant prostate cancer

Authors
Allen, T; Lipton, G; Sibley, AB; Healy, P; Patierno, B; Lacroix, B; Patierno, S; Owzar, K; Hyslop, T; George, DJ; Freedman, JA
MLA Citation
Allen, Tyler, et al. “Abstract 3507: Race-related genetic variation and response to secondary hormonal therapy in metastatic castration-resistant prostate cancer.” Epidemiology, American Association for Cancer Research, 2020. Crossref, doi:10.1158/1538-7445.am2020-3507.
URI
https://scholars.duke.edu/individual/pub1476013
Source
crossref
Published In
Epidemiology
Published Date
DOI
10.1158/1538-7445.am2020-3507

Abstract B061: Mechanistic and functional interrogation of novel ancestry-related alternatively spliced androgen receptor signal genes in prostate cancer

Authors
Onyenwoke, RU; Freedman, JA; Patierno, BM; Eze, C; Dayo, A; George, DJ; Patierno, SR
MLA Citation
Onyenwoke, Rob U., et al. “Abstract B061: Mechanistic and functional interrogation of novel ancestry-related alternatively spliced androgen receptor signal genes in prostate cancer.” Poster Presentations  Proffered Abstracts, American Association for Cancer Research, 2020. Crossref, doi:10.1158/1538-7755.disp18-b061.
URI
https://scholars.duke.edu/individual/pub1467307
Source
crossref
Published In
Poster Presentations Proffered Abstracts
Published Date
DOI
10.1158/1538-7755.disp18-b061